Literature DB >> 29016747

Five year trends (2008-2012) in cardiac implantable electrical device utilization in five European nations: a case study in cross-country comparisons using administrative databases.

Helen Banks1, Aleksandra Torbica1, Cinzia Valzania2, Yauheniya Varabyova3, Valentina Prevolnik Rupel4, Rod S Taylor5, Theresa Hunger6, Simon Walker7, Giuseppe Boriani8, Giovanni Fattore1,9.   

Abstract

Aims: Common methodologies for analysis of analogous data sets are needed for international comparisons of treatment and outcomes. This study tests using administrative hospital discharge (HD) databases in five European countries to investigate variation/trends in pacemaker (PM) and implantable cardioverter defibrillator (ICD) implant rates in terms of patient characteristics/management, device subtype, and initial implantation vs. replacement, and compares findings with existing literature and European Heart Rhythm Association (EHRA) reports. Methods and results: HD databases from 2008 to 2012 in Austria, England, Germany, Italy and Slovenia were interrogated to extract admissions (without patient identification) associated with PM and ICD implants and replacements, using direct cross-referencing of procedure codes and common methodology to compare aggregate data. 1 338 199 records revealed 212 952 PM and 62 567 ICD procedures/year on average for a 204.4 million combined population, a crude implant rate of about 104/100 000 inhabitants for PMs and 30.6 for ICDs. The first implant/replacement rate ratios were 81/24 (PMs) and 25/7 (ICDs). Rates have increased, with cardiac resynchronization therapy (CRT) subtypes for both devices rising dramatically. Significant between- and within-country variation persists in lengths of stay and rates (Germany highest, Slovenia lowest). Adjusting for age lessened differences for PM rates, scarcely affected ICDs. Male/female ratios remained stable at 56/44% (PMs) and 79/21% (ICDs). About 90% of patients were discharged to home; 85-100% were inpatient admissions.
Conclusion: To aid in policymaking and track outcomes, HD administrative data provides a reliable, relatively cheap, methodology for tracking implant rates for PMs and ICDs across countries, as comparisons to EHRA data and the literature indicated.

Entities:  

Mesh:

Year:  2018        PMID: 29016747     DOI: 10.1093/europace/eux123

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  5 in total

1.  Incidence of magnet mode in patients with implantable cardioverter defibrillators.

Authors:  Gesa von Olshausen; Johanna Schorr; Christian Grebmer; Severin Weigand; Patrick Blažek; Amir Brkic; Lena Friedrich; Verena Semmler; Christof Kolb; Carsten Lennerz
Journal:  J Interv Card Electrophysiol       Date:  2019-10-16       Impact factor: 1.900

2.  Transvenous Lead Extraction in Patients with Cardiac Implantable Device: The Impact of Systemic and Local Infection on Clinical Outcomes-An ESC-EHRA ELECTRa (European Lead Extraction Controlled) Registry Substudy.

Authors:  Igor Diemberger; Luca Segreti; Christopher A Rinaldi; Jesper Hastrup Svendsen; Andrzej Kutarski; Arwa Younis; Cécile Laroche; Christophe Leclercq; Barbara Małecka; Przemyslaw Mitkowski; Maria Grazia Bongiorni
Journal:  Biology (Basel)       Date:  2022-04-18

3.  Variation in regional implantation patterns of cardiac implantable electronic device in Switzerland.

Authors:  Lucy Bolt; Maria M Wertli; Alan G Haynes; Nicolas Rodondi; Arnaud Chiolero; Radoslaw Panczak; Drahomir Aujesky
Journal:  PLoS One       Date:  2022-02-16       Impact factor: 3.240

Review 4.  Complications of Cardiac Resynchronization Therapy: Comparison of Safety Outcomes from Real-world Studies and Clinical Trials.

Authors:  Naga Venkata K Pothineni; Suhas Gondi; Tharian Cherian; Swathi Kovelamudi; Robert D Schaller; Dhanunjaya Lakkireddy; Rakesh Gopinathannair; Abhishek Deshmukh
Journal:  J Innov Card Rhythm Manag       Date:  2022-08-15

5.  Severe intestinal malabsorption associated with ACE inhibitor or angiotensin receptor blocker treatment. An observational cohort study in Germany and Italy.

Authors:  Peter Malfertheiner; Claudio Ripellino; Nazarena Cataldo
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-02-19       Impact factor: 2.890

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.